Innitius and the EIC Accelerator: Reading the Cervix to Time Birth

30 September 20261,116 words6 min

Innitius, trading name of Ultrasound-Innovation Medtech S.L. and led by CEO and co-founder Rubén Molina, develops CerviSense, formerly FineBirth, a probe that measures the consistency of the cervix with torsional waves and uses AI to judge the risk of preterm birth. Its EIC application said threatened preterm labour affects 45 million pregnancies a year and that current methods "are ineffective at detecting true events", and asked for €2.5 million "to fully develop and validate our AI software, do a multicentre pivotal clinical trial, and obtain regulatory approval", according to CORDIS.

The European Innovation Council granted €2,342,836 towards a €3.35 million project from April 2023 to March 2026. The only published report, for the first year, lists an FDA pre-submission, a preliminary health technology assessment, a beta device design that still needed "additional iteration", research into a second use in labour induction, and a pivotal trial design sent to the FDA. In June 2025 Innitius announced that Spain's medicines agency had approved the CerviSense pivotal study: 457 patients in hospitals in Spain and Germany, with a pilot phase started in April 2025 and a pivotal phase of about 14 months to follow.

€2.34MEIC grant, 70% of a €3.35M project
457Patients planned in the pivotal study
17Hospitals planned in Spain and Germany
PendingPivotal trial results

Company file

Legal entity
Ultrasound-Innovation Medtech S.L. (Innitius), Bizkaia
Origin
Spin-off of the University of Granada and Andalusian Health Service, 2017
CEO
Rubén Molina, co-founder
Product
CerviSense (formerly FineBirth) probe and AI software
Indications
Threatened preterm labour, preterm labour prognosis, induction of labour
EIC project
FineBirth, 1 Apr 2023 to 31 Mar 2026, closed
EIC funding
Blended finance

Where Innitius Stands Now

The CerviSense product page describes the device as "CE-certified" and presents one probe with AI models for three uses across pregnancy. Innitius announced CE marking in October 2025, FemTech Insider reported; the EIC impact profile lists European certification of the hardware platform in 2025 and certification for the threatened preterm labour indication as planned for 2027. In its 2024 review, Innitius said it had moved from a single product to a platform, manufactured and validated the first eight probes of a new design, and completed its first clinical trial, "surpassing our targets for sensitivity (70%) and specificity (90%)", and that a trial at King's College on preterm labour prognosis would start in early 2025. The pivotal study's ClinicalTrials.gov record (last updated May 2025) lists it as recruiting, with estimated completion in April 2027 and no results posted. Sources reviewed on 7 November 2026 show no published pivotal results or announced sales.

The record

From Granada spin-off to a pivotal preterm labour trial

Innitius used its EIC project to design a market version of its device, consult the FDA and prepare a pivotal trial. The device, now called CerviSense, received CE marking for its hardware platform in 2025, per the company and the EIC, with the threatened preterm labour indication planned for 2027; the pilot phase of the pivotal study started in 2025.

  1. 2017Company foundedUniversity of Granada and Andalusian Health Service spin-off
  2. Oct 2022EIC Accelerator cut-offFineBirthblended finance
  3. Apr 2023EIC project starts€3.35M project€2.34M grant
  4. 2023-24FDA pre-submissionPivotal trial design sent to FDA
  5. 2024Clinical trial 1 doneSensitivity and specificity targets beaten, per company
  6. Apr 2025Pilot phase startsAEMPS-approved study; 457 patients planned
  7. Oct 2025CE marking announcedHardware platform, per company
  8. Mar 2026EIC project endsCORDIS lists project closed

CORDIS and Innitius.

"This is a major step forward as we continue building the evidence needed to bring CerviSense to clinical practice."

Rubén Molina, CEO and co-founder, Innitius, June 2025

The Technology: Measuring Softness, Not Length

Before birth the cervix softens and shortens. Doctors judge softness by touch or measure length by ultrasound; Innitius says 85% of women hospitalised for threatened preterm labour turn out not to be in true labour. CerviSense sends torsional waves into cervical tissue to measure its consistency objectively, and an AI model combines the result with the patient's history to give a risk assessment.

The problem

How current labour diagnostics fall short, per Innitius

Company figures: share of women hospitalised for threatened preterm labour who turn out to be false positives, share of preterm cases missed at the mid-trimester scan, and share of labour inductions that fail.

Innitius website, company figures.

What the EIC Project Promised, and What CORDIS Shows

The EIC project

The EU contribution covered 70% of a €3.35M project

The FineBirth project ran from April 2023 to March 2026. CORDIS lists it as closed but publishes only the first-year report.

CORDIS project 190144075. Values in € millions.

The project promised AI validation, a pivotal trial and regulatory approval. The first-year report covers planning and design. The pivotal study's pilot phase started during the project but, with about 14 months for the main phase to follow, it extends beyond the project's end in March 2026. The company announced CE marking in 2025, with certification for the threatened preterm labour indication planned for 2027 according to the EIC, but CORDIS publishes no report on the last two years and no trial results. CORDIS lists the project as closed.

  1. Market device designDeliveredNew probes validated.
  2. Pivotal trialRunningPilot phase started April 2025.
  3. CE markingPartialPreterm indication due 2027.
  4. Validated AI accuracyUnverifiedNo published results.

The trial

Hospitals planned for the CerviSense pivotal study

The study plans to enrol 457 women with symptoms of threatened preterm labour, first in a pilot phase in four Spanish hospitals, then a pivotal phase across Spain and Germany.

Innitius, June 2025.

The Money

Innitius's research is also funded by the regional government of Andalusia, according to acknowledgements in its published studies. It closed a €1.8 million round led by Clave Capital and Nara Capital in February 2023, FemTech World reported, the EIC profile lists a €3 million growth round closed in 2024, and in October 2025 the company was reported to be raising a Series A. Whether the EIC Fund invested under the blended award is not public in the sources reviewed. Revenue is not public.

What Cannot Be Checked

Questions for the EIC

What the pivotal trial has shown so far, which notified body issued the CE certificate and for which indication, whether the EIC Fund invested, and when hospitals can buy CerviSense are not public.

Why Europe Should Care

Many women with preterm labour symptoms receive unnecessary treatment, while others are sent home without adequate care, Innitius says. An objective test would improve care and save money. The EIC funded Innitius's path to a pivotal trial in European hospitals; the evidence is being gathered now.

What the project promised

Validated AI, a completed pivotal trial and regulatory approval for a preterm labour test.

What the record shows

A new device, a pivotal study approved in Spain and planned for 17 hospitals with its pilot phase begun, CE marking announced in 2025, and no published results.

The Verdict

Trial under way, proof pending

Innitius built its device and began the pilot phase of the pivotal study the EIC grant supported. Whether CerviSense works as claimed will be known only when those results are published.

Innitius and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.

Industry

HealthMedical devices

Focus
  • Women's health devices
Technologies
  • Ultrasound
  • Artificial intelligence
Keywords
  • Preterm birth
  • Cervical assessment
  • Obstetrics
  • Labour induction